中信证券股份有限公司 关于上海泓博智源医药股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：泓博医药 | | --- | --- | | 保荐代表人姓名：王琦 | 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 | 联系电话：010-60838329 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据《上海泓博智源医药股份有限公司内 部控制评价报告》、《上海泓博智源医药股份 | | | 有限公司内部控制审计报告》，发行人有效执 | | | 行了相关规章制度。 | | 3.募集资金 ...

关于上海泓博智源医药股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：泓博医药 | | --- | | （以下简称"中信证券"或"保荐人"） | | 保荐代表人姓名：王琦 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 联系电话：010-60838329 | | 现场检查人员姓名：王琦 | | 现场检查对应期间：2024 年 1 月 1 日-2024 年 12 月 31 日 | | 现场检查时间：2025 年 月 日 4 24 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | 文件，查看上市公司生产经营场所，对上市公司董事长、董事会秘书、财务总监 | | 进行访谈。 | | 1.公司章程和公司治理制度是否完备、合规 是 | | 2.公司 ...

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第四届董事会第二次会议通知于 2025 年 4 月 19 日以邮件的形式送达全体董事。会议于 2025 年 4 月 25 日上午 10:00 在上 海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方式召开。会议应 出席董事 7 名，实际出席 7 名。本次会议由董事长 Ping Chen 博士主持召开，公司监事、高 级管理人员列席了会议。会议召开及表决程序符合《中华人民共和国公司法》及《上海泓博 智源医药股份有限公司章程》的有关规定。 证券代码：301230 证券简称：泓博医药 公告编号：2025-036 上海泓博智源医药股份有限公司 第四届董事会第二次会议决议公告 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）披露的《2025 年第一季度报告》。 二、董事会会议审议情况 经出席会议的全体董事认真审议，通过了如下议案： 1、审议通过《关于<2025 年第一季度报告>的议案》 经与会董事审议，公司 20 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-038 上海泓博智源医药股份有限公司 关于 2025 年第一季度计提信用减值损失 及资产减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次计提信用减值损失及资产减值损失情况概述 （一）本次计提信用减值损失及资产减值损失的原因 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》、《企业会计准则》等相关规定的要求，为更加真实、准确地反映上海泓博智源 医药股份有限公司（以下简称"公司"）的财务状况、资产价值及经营情况，基于谨慎 性原则，公司对截至 2025 年 3 月 31 日合并报表范围内的各类资产进行了全面检查和 减值测试，对可能发生减值损失的相关资产计提了减值损失。 （二）本次计提信用减值损失及资产减值损失的资产范围和总金额 公司 2025 年第一季度各项资产计提信用减值损失共计 178.27 万元，资产减值损失 共计 100.78 万元，合计 279.05 万元，具体情况如下： 单位：万元 | 类型 | 项目 | 2025 年第一季度计提 金额 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-037 上海泓博智源医药股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第四届监事会第二次会议通 知于 2025 年 4 月 19 日以邮件形式送达全体监事。会议于 2025 年 4 月 25 日上午 10:30 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方 式召开。本次会议由监事会主席刘国东先生主持召开，应出席监事 5 名，实际出席 5 名。会议召开及表决程序符合《中华人民共和国公司法》及《上海泓博智源医药股份 有限公司章程》的有关规定。 二、监事会会议审议情况 经出席会议的全体监事认真审议，通过了如下议案： 1、审议通过《关于<2025 年第一季度报告>的议案》 经审核，监事会认为：公司《2025 年第一季度报告》编制和审核程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第 一季度的财务状况和经营成 ...

Financial Performance - The company's revenue for Q1 2025 was ¥169,429,129.41, representing a 29.61% increase compared to ¥130,725,745.26 in the same period last year[8]. - Net profit attributable to shareholders reached ¥11,973,873.82, a significant increase of 226.47% from ¥3,667,660.56 in the previous year[8]. - The net profit excluding non-recurring gains and losses was ¥9,683,298.46, marking a 1,448.20% increase from ¥625,453.36 year-on-year[8]. - The basic and diluted earnings per share were both ¥0.09, reflecting a 200.00% increase compared to ¥0.03 in the same period last year[8]. - Operating profit for the current period was ¥11,119,439.09, significantly higher than ¥1,764,717.02 from the previous period, marking a substantial increase[21]. - Net profit for the current period reached ¥11,973,873.82, compared to ¥3,667,660.56 in the previous period, representing a growth of 226.5%[22]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,331,270,025.58, a 1.13% increase from ¥1,316,426,388.19 at the end of the previous year[8]. - Total liabilities amounted to ¥285,025,808.71, slightly up from ¥283,728,930.39 in the previous period[19]. - The company's cash and cash equivalents at the end of the reporting period amount to ¥80,859,628.03, a decrease from ¥84,519,980.92 at the beginning of the period[17]. - Total assets at the end of the reporting period are ¥1,331,270,025.58, compared to ¥1,316,426,388.19 at the beginning[18]. - The total non-current assets decreased to ¥746,779,546.00 from ¥762,108,412.74[18]. Cash Flow - The net cash flow from operating activities was negative at -¥1,876,307.90, a decline of 120.23% compared to ¥9,275,848.83 in the same period last year[8]. - Cash flow from operating activities was ¥118,756,546.12, an increase from ¥109,738,736.88 in the previous period[24]. - Net cash flow from operating activities was -$1.88 million, a decrease from $9.28 million in the previous period, indicating a decline in operational efficiency[25]. - Cash inflow from operating activities totaled $128.08 million, slightly lower than $133.02 million in the previous period, showing stable operational cash generation[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,315[14]. - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.71% of shares, totaling 38,675,000 shares[14]. - The top ten shareholders include several investment firms, with the largest being Hongbo Zhiyuan, followed by An Rongchang and Jiang Shengli, indicating a concentration of ownership[14]. Operating Costs and Expenses - Total operating costs amounted to ¥157,965,262.18, up from ¥135,325,810.41, reflecting a growth of 16.8%[20]. - Research and development expenses decreased to ¥8,726,167.99 from ¥11,274,826.18, a reduction of 22.6%[21]. - Cash outflow for employee compensation was $67.05 million, an increase from $62.02 million, reflecting rising labor costs[25]. Government Support and Other Income - The company received government subsidies amounting to ¥615,660.33 during the reporting period, which are closely related to its normal business operations[9]. - The company reported a decrease in other comprehensive income, with a net amount of -¥81,158.69 for the current period[22]. - The company received $1.55 million in tax refunds, compared to $0.52 million previously, indicating improved tax recovery[25]. Borrowings and Receivables - Short-term borrowings increased by 76.45% to ¥17,664,171.34, up from ¥10,011,000.00[12]. - Accounts receivable increased to ¥124,302,105.64 from ¥98,645,259.36, reflecting a growth of approximately 26%[18]. - The company reported a significant increase in accounts receivable, which rose by 739.78% to ¥9,312,016.35 from ¥1,108,865.20[12].

泓博医药（301230）公告，2025年第一季度营业收入1.69亿元，同比增长29.61%。净利润1197.39万 元，同比增长226.47%。 ...

Group 1 - The core viewpoint of the news is that the implementation plan for the digital transformation of the pharmaceutical industry in China aims to achieve comprehensive digitalization by 2030, enhancing innovation capabilities and establishing a complete industrial ecosystem [1][2] - The plan includes four major actions: empowering digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation, with 14 key tasks to improve the overall capability of the pharmaceutical industry's digital transformation [1][2] - The focus areas of the plan include pharmaceutical research and development, production, management decision-making, quality assurance, circulation and traceability, and contract research and production services, providing a clear pathway for collaboration between pharmaceutical companies and IT service providers [1][2] Group 2 - The release of the plan signifies a new phase of high-quality development driven by data and intelligent empowerment in the pharmaceutical industry, which is expected to reshape the industry landscape through technologies like AI in drug development and smart manufacturing [2] - The AI pharmaceutical market is projected to grow significantly, from $1.38 billion in 2023 to $2.994 billion by 2026, with a compound annual growth rate of 30.47% from 2021 to 2026 [3] - Major pharmaceutical companies are expected to enhance drug discovery efficiency by over 50% through AI integration, which will lead to better resource allocation in research and healthcare [3] Group 3 - Notable companies in the sector include WuXi AppTec, which is projected to achieve a revenue of 39.241 billion yuan in 2024, with a 5.2% year-on-year growth excluding COVID-19 projects [4] - Kanglong Chemical is expected to report a revenue of 12.276 billion yuan in 2024, reflecting a 6.39% year-on-year increase, while its net profit is anticipated to grow by 12.01% [4] - Yidu Technology focuses on AI in healthcare, providing innovative solutions across various fields, including public health and new drug development [4]

Core Insights - The company reported a revenue of 544 million yuan for 2024, representing a year-on-year growth of 11.18%, while the net profit attributable to shareholders decreased by 54.59% to 17.08 million yuan [1] - The company is a new drug research and development service provider, increasing its R&D investment, which amounted to 47.26 million yuan, accounting for 8.68% of total revenue [1] - The compound annual growth rate (CAGR) for revenue from 2022 to 2024 is 6.70%, while the CAGR for R&D expenses is significantly higher at 40.21% [1] R&D and Technical Platforms - As of the end of 2024, the company has delivered a total of 55 candidate drug molecules to clients, with 10 new additions compared to 2023, and 47 of these are First-in-Class (FIC) projects, making up 85.45% of the total [1] - The company has established 12 core technology platforms since 2019, including CADD/AIDD, enzyme chemistry, photochemistry, and others, to enhance its technological capabilities [1] Business Development - The CADD/AIDD technology platform has supported 80 new drug projects, with 6 entering clinical Phase I and 1 entering clinical Phase II, and the number of clients utilizing CADD/AIDD services has reached 40 [2] - The company has intensified its marketing and promotional efforts, participating in 19 domestic and international exhibitions and forums during the reporting period, leading to progress in active customer numbers and new order amounts [2] - The company provides comprehensive services for global pharmaceutical and biotechnology companies, focusing on drug discovery, pharmaceutical process development, and customized/commercial production of active pharmaceutical ingredients and key intermediates [2]